Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PAX2
REST API REST API
Homo sapiens
PAX2 is differentially expressed in 183 experiments: 98 organism parts: kidney, esophagus, ... (96 more);, 145 disease states: normal, breast carcinoma, ... (143 more);, 45 cell types 227 cell lines 19 compound treatments and 63 other conditions.
Orthologs Pax2 (Mus musculus)   F6WAV5_CIOIN (Ciona intestinalis)   F1NEQ7_CHICK (Gallus gallus)   F6VTG6_CIOIN (Ciona intestinalis)   PAX2 (Bos taurus)   Pax2 (Rattus norvegicus)   sv (Drosophila melanogaster)   ENSXETG00000014206 (Xenopus laevis)   PAX2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, negative regulation of programmed cell death, regulation of transcription, DNA-dependent, cell fate determination, stem cell differentiation, protein complex, transcription, DNA-dependent, visual perception, negative regulation of apoptosis, mesodermal cell fate specification, anti-apoptosis, transcription from RNA polymerase II promoter, glial cell differentiation, protein kinase B signaling cascade, positive regulation of transcription from RNA polymerase II promoter, microtubule organizing center, multicellular organismal development, nucleus, axonogenesis, brain morphogenesis, positive regulation of transcription, DNA-dependent, negative regulation of caspase activity, cellular response to retinoic acid, metanephric distal convoluted tubule development, cellular response to glucose stimulus, optic nerve morphogenesis, mesenchymal to epithelial transition involved in metanephros morphogenesis, urogenital system development, neural tube closure, optic nerve development, branching involved in ureteric bud morphogenesis, mesonephros development, negative regulation of cytolysis, optic cup morphogenesis involved in camera-type eye development, nephric duct formation, metanephric epithelium development, protein-DNA complex, positive regulation of epithelial cell proliferation, cochlea morphogenesis, positive regulation of branching involved in ureteric bud morphogenesis, cellular response to hydrogen peroxide, cochlea development, centriolar satellite, retinal pigment epithelium development, camera-type eye development, inner ear morphogenesis, mesenchymal to epithelial transition, metanephric mesenchymal cell differentiation, superoxide-generating NADPH oxidase activity, metanephric collecting duct development, pronephric field specification, pronephros development, core promoter proximal region sequence-specific DNA binding, positive regulation of metanephric DCT cell differentiation, negative regulation of mesenchymal stem cell apoptosis involved in metanephric nephron morphogenesis, metanephric nephron tubule formation, regulation of metanephros size, ureter development, positive regulation of metanephric glomerulus development, negative regulation of reactive oxygen species metabolic process, metanephric mesenchyme development, reactive oxygen species metabolic process, transcription regulatory region DNA binding, regulation of metanephric nephron tubule epithelial cell differentiation, positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis, ureter maturation, optic nerve structural organization, vestibulocochlear nerve formation, optic chiasma development, positive regulation of optic nerve formation
InterPro Term Paired_box_N, Pax2_C
UniProt Accession Q02962, Q5SZP1, Q6YFJ8
Gene-Disease Assocation PAPILLORENAL SYNDROME
Search EB-eye ENSG00000075891
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-22639, E-GEOD-19639, E-GEOD-18005, ... (23 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
NCIH661
1
E-MTAB-37
MKN28
1
E-GEOD-15460
REC1
1
E-MTAB-37
HEK293
1
E-MTAB-62
221 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (30 experiments)

Factor Value U/D Experiments
fibroblast
2
E-GEOD-3920, E-MEXP-466
epithelial cell
2
E-GEOD-10797, E-GEOD-4483
monocyte
1
E-MEXP-583
CD34+ hematopoietic progenitor cell
1
1
E-GEOD-19240
macrophage
1
E-GEOD-3982
neutrophil
1
E-GEOD-12662
39 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-GEOD-1869, E-MEXP-2069, ... (39 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
prostate carcinoma
2
E-MTAB-62, E-MEXP-2034
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
1
2
E-GEOD-5823, E-MTAB-37, E-MTAB-62
alzheimers disease
1
E-MTAB-62
inhalation injury
1
E-GEOD-19743
139 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-15205, E-GEOD-412, ... (12 experiments)

Factor Value U/D Experiments
none
1
2
E-GEOD-412, E-GEOD-5824, E-GEOD-2803
sapphyrin PCI-2054
1
E-GEOD-6400
ethanol
1
E-MEXP-2241
Cxcl12
1
1
E-GEOD-7307
TGF
1
1
E-GEOD-15205
unknown
1
E-GEOD-7307
13 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
84
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-4667

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-GEOD-20847

Genotype
studied in E-TABM-1029, E-GEOD-22056, E-GEOD-12662, E-GEOD-2466, E-MEXP-421, ... (9 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1446, E-GEOD-10315

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-2748

Individual
studied in E-GEOD-1926, E-MEXP-2069, E-TABM-26, E-GEOD-20876, E-GEOD-16363, ... (31 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-12662

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Qpcr egfr dct
studied in E-GEOD-5851

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Processing time: 0.257 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM